Clinical Applications of Novel ERG Immunohistochemistry in Prostate Cancer Diagnosis and Management

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Advances in Anatomic Pathology

• Publication date

  2013-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1097/PAP.0b013e3182862ac5PMID 23399797
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The diagnostic use of ERG in resolving an "atypical glands suspicious for cancer" diagnosis in prostate biopsies beyond that provided by basal cell and α-methylacyl-CoA-racemase markers.

  2013cited by this paper
• The TMPRSS2:ERG Rearrangement, ERG Expression, and Prostate Cancer Outcomes: A Cohort Study and Meta-analysis

  2012cited by this paper
• Clinical potential of the ERG oncoprotein in prostate cancer

  2012cited by this paper
• ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer

  2012cited by this paper
• Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies.

  2012cited by this paper
• ERG Rearrangement for Predicting Subsequent Cancer Diagnosis in High-Grade Prostatic Intraepithelial Neoplasia and Lymph Node Metastasis

  2012cited by this paper
• High level of Ets‐related gene expression has high specificity for prostate cancer: a tissue microarray study of 11 483 cancers

  2012cited by this paper
• Expression of ERG protein, a prostate cancer specific marker, in high grade prostatic intraepithelial neoplasia (HGPIN): lack of utility to stratify cancer risks associated with HGPIN

  2012cited by this paper
• ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer—a comparative study of two monoclonal antibodies

  2012cited by this paper
• Atypical Cribriform Lesions of the Prostate: Clinical Significance, Differential Diagnosis and Current Concept of Intraductal Carcinoma of the Prostate

  2012cited by this paper
• Expression of ERG, an Ets family transcription factor, identifies ERG-rearranged Ewing sarcoma

  2012cited by this paper
• The Diagnostic Utility of Novel Immunohistochemical Marker ERG in the Workup of Prostate Biopsies With “Atypical Glands Suspicious for Cancer”

  2011cited by this paper
• ERG Transcription Factor as an Immunohistochemical Marker for Vascular Endothelial Tumors and Prostatic Carcinoma

  2011cited by this paper
• Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice

  2011cited by this paper
• ERG gene rearrangement status in prostate cancer detected by immunohistochemistry

  2011cited by this paper
• Immunohistochemistry for ERG Expression as a Surrogate for TMPRSS2-ERG Fusion Detection in Prostatic Adenocarcinomas

  2011cited by this paper
• TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate.

  2011cited by this paper
• The Utility of ERG/P63 Double Immunohistochemical Staining in the Diagnosis of Limited Cancer in Prostate Needle Biopsies

  2011cited by this paper
• Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer.

  2011cited by this paper
• ERG Status Is Unrelated to PSA Recurrence in Radically Operated Prostate Cancer in the Absence of Antihormonal Therapy

  2011cited by this paper
• ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification

  2010cited by this paper
• ETS Gene Aberrations in Atypical Cribriform Lesions of the Prostate: Implications for the Distinction Between Intraductal Carcinoma of the Prostate and Cribriform High-grade Prostatic Intraepithelial Neoplasia

  2010cited by this paper
• Antibody-based detection of ERG rearrangement-positive prostate cancer.

  2010cited by this paper
• Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer

  2010cited by this paper
• Atypical Cribriform Lesions of the Prostate: Relationship to Prostatic Carcinoma and Implication for Diagnosis in Prostate Biopsies

  2010cited by this paper
• The Discovery of Common Recurrent Transmembrane Protease Serine 2 (TMPRSS2)-Erythroblastosis Virus E26 Transforming Sequence (ETS) Gene Fusions in Prostate Cancer: Significance and Clinical Implications

  2009cited by this paper
• Prevalence of TMPRSS2-ERG Fusion Prostate Cancer among Men Undergoing Prostate Biopsy in the United States

  2009cited by this paper
• Overexpression of Prostate-Specific TMPRSS2(exon 0)-ERG Fusion Transcripts Corresponds with Favorable Prognosis of Prostate Cancer

  2009cited by this paper
• TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy.

  2009cited by this paper
• Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression

  2009cited by this paper
• Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma

  2009cited by this paper
• Aberrant Diffuse Expression of p63 in Adenocarcinoma of the Prostate on Needle Biopsy and Radical Prostatectomy: Report of 21 Cases

  2009cited by this paper
• Characterization of TMPRSS2-ERG Fusion High-Grade Prostatic Intraepithelial Neoplasia and Potential Clinical Implications

  2008cited by this paper
• Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome

  2008cited by this paper
• Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer

  2008cited by this paper
• Partial Atrophy in Prostate Needle Biopsies: A Detailed Analysis of Its Morphology, Immunophenotype, and Cellular Kinetics

  2008cited by this paper
• Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer.

  2008cited by this paper
• Aberrant Diffuse Expression of p63 in Adenocarcinoma of the Prostate on Needle Biopsy and Radical Prostatectomy: Report of 21 Cases

  2008cited by this paper
• A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer.

  2008cited by this paper
• CHARACTERIZATION OF TMPRSS2-ETS GENE ABERRATIONS IN ANDROGEN INDEPENDENT METASTATIC PROSTATE CANCER

  2008cited by this paper
• Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer.

  2008cited by this paper
• TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort

  2007cited by this paper
• Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases.

  2007cited by this paper
• Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression

  2007cited by this paper
• Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer

  2007cited by this paper
• Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care.

  2006cited by this paper
• Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome

  2006cited by this paper
• TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer.

  2006cited by this paper
• TMPRSS2-ERG Fusion Prostate Cancer: An Early Molecular Event Associated With Invasion

  2006cited by this paper
• Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

  2006cited by this paper
• Whole-pelvis, "mini-pelvis," or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial.

  2006cited by this paper
• Immunohistochemistry in diagnostic surgical pathology of the prostate.

  2005cited by this paper
• Diagnostic utility of immunohistochemistry in morphologically difficult prostate cancer: review of current literature

  2005cited by this paper
• Comparison of monoclonal antibody (P504S) and polyclonal antibody to alpha methylacyl‐CoA racemase (AMACR) in the work‐up of prostate cancer

  2005cited by this paper
• Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome

  2005cited by this paper
• Usefulness of basal cell cocktail (34betaE12 + p63) in the diagnosis of atypical prostate glandular proliferations.

  2004cited by this paper
• Diagnostic usefulness of monoclonal antibody P504S in the workup of atypical prostatic glandular proliferations.

  2003cited by this paper
• Comparison of the Basal Cell-Specific Markers, 34&bgr;E12 and p63, in the Diagnosis of Prostate Cancer

  2002cited by this paper
• Can Basal Cells Be Seen in Adenocarcinoma of the Prostate?: An Immunohistochemical Study Using High Molecular Weight Cytokeratin (Clone 34&bgr;E12) Antibody

  2002cited by this paper

• Immunohistochemical evaluation of ERG expression in soft tissue tumours: a tissue microarray study of 489 cases

  2025cites this paper
• Prognostic value of E‑26 transformation‑specific‑related gene in prostate cancer based on immunohistochemistry analysis

  2023cites this paper
• Diagnostic utility of immunohistochemical markers alpha methyl acyl coA racemase (AMACR) and Ets related gene (ERG) in prostate cancer.

  2022cites this paper
• Diagnostic Values of Immunohistochemistry in Bladder Cancer

  2021cites this paper
• Nanoscale materials-based hybrid frameworks modified electrochemical biosensors for early cancer diagnostics: An overview of current trends and challenges

  2021cites this paper
• Mapping Isoform Abundance and Interactome of the Endogenous TMPRSS2-ERG Fusion Protein by Orthogonal Immunoprecipitation–Mass Spectrometry Assays

  2021cites this paper
• Integrated immunohistochemical and molecular analysis improves diagnosis of high-grade carcinoma in the urinary bladder of patients with prior radiation therapy for prostate cancer

  2020cites this paper
• Neuropilin‐2 is an independent prognostic factor for shorter cancer‐specific survival in patients with acinar adenocarcinoma of the prostate

  2020cites this paper
• Mapping Isoform Abundance and Interactome of the Endogenous TMPRSS2-ERG Fusion Protein with Orthogonal Immunoprecipitation-Mass Spectrometry Assays

  2020cites this paper
• Molecular Biology of Prostate Cancer and Role of Genomic Testing in Diagnosis and Prognosis of Prostate Cancer

  2019cites this paper
• Prostate-specific markers to identify rare prostate cancer cells in liquid biopsies

  2018cites this paper
• RNA Analysis as a Tool to Determine Clinically Relevant Gene Fusions and Splice Variants.

  2018cites this paper
• Prostate Cancer Tissue Diagnosis

  2018cites this paper
• The Significance of ERG and Androgen Receptor Expression in Adenocarcinoma Prostate.

  2018cites this paper
• Morphological and Immunohistochemical Biomarkers in Distinguishing Prostate Carcinoma and Urothelial Carcinoma: A Comprehensive Review

  2018cites this paper
• Practical Applications of Immunohistochemistry in the Diagnosis of Genitourinary Tumors.

  2017cites this paper
• Immunohistochemistry, carcinomas of unknown primary, and incidence rates.

  2017cites this paper
• Patohistološka dijagnostka karcinoma prostate

  2017cites this paper
• Atypical intraductal proliferation and intraductal carcinoma of the prostate on core needle biopsy: a comparative clinicopathological and molecular study with a proposal to expand the morphological spectrum of intraductal carcinoma

  2017cites this paper
• Molecular Pathology of Prostate Cancer

  2017cites this paper
• Evaluation of ERG and PTEN protein expression in cribriform architecture prostate carcinomas.

  2017cites this paper
• Improvement of diagnostic agreement among pathologists in resolving an "atypical glands suspicious for cancer" diagnosis in prostate biopsies using a novel "Disease-Focused Diagnostic Review" quality improvement process.

  2016cites this paper
• ERG expression in prostate cancer: biological relevance and clinical implication

  2016influential citation
• Prognostic value of ERG, PTEN, CRISP3 and SPINK1 in predicting biochemical recurrence in prostate cancer

  2016cites this paper
• ERG overexpression and multifocality predict prostate cancer in subsequent biopsy for patients with high-grade prostatic intraepithelial neoplasia.

  2016cites this paper
• Recent advances in prostate cancer pathology: Gleason grading and beyond

  2016cites this paper
• The emerging complexity of gene fusions in cancer

  2015cites this paper
• Heterogeneity of PTEN and ERG expression in prostate cancer on core needle biopsies: implications for cancer risk stratification and biomarker sampling.

  2015cites this paper
• Immunohistochemistry as a Surrogate for Molecular Testing: A Review

  2015cites this paper
• Expression of ROS1 predicts ROS1 gene rearrangement in inflammatory myofibroblastic tumors

  2015cites this paper
• New Molecular Markers of Diagnosis and Prognosis in Prostate Cancer

  2015influential citation
• Quantitative analysis of ERG expression and its splice isoforms in formalin-fixed, paraffin-embedded prostate cancer samples: association with seminal vesicle invasion and biochemical recurrence.

  2014cites this paper
• A DNA hypermethylation profile reveals new potential biomarkers for prostate cancer diagnosis and prognosis

  2014cites this paper
• Prognostic Histopathological and Molecular Markers on Prostate Cancer Needle-Biopsies: A Review

  2014cites this paper
• Novel uses of immunohistochemistry in the diagnosis and classification of soft tissue tumors

  2014cites this paper
• ANALY TICAL AND QUANTITATIVECYTOPATHOLOGY

  2014cites this paper
• Tumors of the genitourinary system

  2014cites this paper
• Contemporary update on pathology-related issues on routine workup of prostate biopsy: sectioning, tumor extent measurement, specimen orientation, and immunohistochemistry.

  2014cites this paper
• Considering race and the potential for ERG expression as a biomarker for prostate cancer.

  2014cites this paper
• Current and Proposed Molecular Diagnostics in a Genitourinary Service Line Laboratory at a Tertiary Clinical Institution

  2014cites this paper
• ERG positive prostatic cancer may show a more angiogenetic phenotype.

  2014cites this paper
• Utility of ERG Versus AMACR Expression in Diagnosis of Minimal Adenocarcinoma of the Prostate in Needle Biopsy Tissue

  2014cites this paper
• Frequency of ERG-positive prostate carcinoma in Polands.

  2013cites this paper
• Frequent TMPRSS2-ERG rearrangement in prostatic small cell carcinoma detected by fluorescence in situ hybridization: the superiority of fluorescence in situ hybridization over ERG immunohistochemistry.

  2013influential citation
• Newly Available Antibodies With Practical Applications in Surgical Pathology

  2013cites this paper
• Molecular Clues Assist in the Cancer Clinic

  2013cites this paper
• Benign Mimics of Prostate Carcinoma

  2012cites this paper